Denosumab for the prevention of osteoporotic fractures in post-menopausal women: A NICE single technology appraisal

PharmacoEconomics

Volumn 29, Issue 11, 2011, Pages 951-961

  Scotland, Graham ^a   Waugh, Norman ^a   Royle, Pamela ^a   McNamee, Paul ^a   Henderson, Rob ^b   Hollick, Rosemary ^c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b NHS HIGHLAND   (United Kingdom)

^c ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

Cost effectiveness; Cost utility; Decision making; Denosumab; Formularies; Fracture; Osteoporosis; Postmenopausal osteoporosis.

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; STRONTIUM RANELATE; ZOLEDRONIC ACID;

CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG SAFETY; DRUG TOLERABILITY; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; INCIDENCE; NATIONAL HEALTH ORGANIZATION; NURSING HOME; OSTEOPOROSIS; POSTMENOPAUSE; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SENSITIVITY ANALYSIS; TREATMENT CONTRAINDICATION; VERTEBRA FRACTURE; WRIST FRACTURE;

ANTIBODIES, MONOCLONAL; BONE DENSITY CONSERVATION AGENTS; COST-BENEFIT ANALYSIS; DRUG APPROVAL; FEMALE; GREAT BRITAIN; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WOMEN'S HEALTH;

EID: 80054104259     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11589310-000000000-00000     Document Type: Review

References (28)

1. National Institute for Health and Clinical Excellence. Guide to the single technology appraisal process. London: NICE, 2009 Oct [online]. Available from URL: http://www.ni ce.org.uk/media/913/06/Guide-to-the-STA-proof-6-26-10- 09.pdf [Accessed 2010 Dec 3]
2. Sculpher M. Single technology appraisal at theUK National Institute for Health and Clinical Excellence: a source of evidence and analysis for decision making internationally. Pharmacoeconomics 2010; 28 (5): 347-9
3. Rodgers M, Griffin S, Paulden M, et al. Alitretinoin for severe chronic hand eczema: A NICE single technology appraisal. Pharmacoeconomics 2010; 28 (5): 351-62
4. Bagust A, Greenhalgh J, Boland A, et al. Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal. Pharmacoeconomics 2010; 28 (6): 439-48
5. Stevenson M, Pandor A. Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal. Pharmacoeconomics 2011; 29 (2): 133-40
6. Dickson R, Bagust A, Boland A, et al. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal. Pharmacoeconomics. In press
7. McKenna C, Maund E, Sarowar M, et al. Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal. Pharmacoeconomics. In press
8. Holmes M, Carroll C, Papaioannou D. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a NICE single technology appraisal. Pharmacoeconomics. In press
9. Boyers D, Jia X, Jenkinson D, et al. Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP): a NICE single technology appraisal. Pharmacoeconomics. In press
10. National Institute for Health and Clinical Excellence. Osteoporotic fractures: denosumab. London: NICE [online]. Available from URL: http://guidance.nice.org.uk/TA/ Wave20/75 [Accessed 2011 Jul 4]
11. National Institute for Health and Clinical Excellence. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. London: NICE, 2010 Jan [online]. Available from URL: http:// www.nice.org.uk/TA160 [Accessed 2010 Dec 3]
12. European Medicines Agency. Prolia: denosumab. European Public Assessment Report (EPAR). London: EMA, 2010 [online]. Available from URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 001120/human-med-001324.jsp&murl=menus/medicines/medicines.jsp&mid= WC0b01ac058001d124&jsenabled=true [Accessed 2010 Dec 3]
13. National Institute for Health and Clinical Excellence. Single technology appraisal (STA): denosumab for the prevention of osteoporotic fractures in postmenopausal women. Manufacturer/sponsor submission of evidence, AmgenUK Ltd. Submitted 22 January 2010, resubmitted 15 February 2010. London: NICE, 2010 Feb [online]. Available from URL: http://www.nice.org.uk/nicemedia/live/12174/49288/ 49288.pdf [Accessed 2010 Dec 3]
14. Scotland G, Royle P, Henderson R, et al. Evidence review: denosumab for the prevention of osteoporotic fractures in post-menopausal women. Aberdeen HTA Group, 2010 [online]. Available from URL: http://www.nice.org.uk/ni cemedia/live/12174/49283/49283.pdf [Accessed 2011 Jul 4]
15. National Institute for Health and Clinical Excellence. Systematic reviews of clinical effectiveness prepared for the guideline 'Osteoporosis: assessment of fracture risk and the prevention of osteoporotic fractures in individuals at high risk'. London: National Collaborating Centre for Nursing and Supportive Care, 2008 Sep [online]. Available from URL: http://www.nice.org.uk/guidance/ index.jsp?action=folder&o=42361 [Accessed 2010 Dec 3]
16. National Institute for Health and Clinical Excellence. Osteoporosis guideline. London: NICE [in development; online]. Available from URL: http://guidance.nice.org.uk/ CG/Wave7/32 [Accessed 2010 Dec 3]
17. Cummings SR, San MJ, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361 (8): 756-65
18. Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997; 50 (6): 683-91 (Pubitemid 27341818)
19. US FDA. Background document for meeting of Advisory Committee forReproductive Health Drugs (August 13, 2009). Denosumab (proposed trade name: PROLIA): Amgen, Inc. Silver Spring (MD): US FDA, 2009 Aug [online]. Available from URL: http://www.fda.gov/downloads/Advisory Committees/ CommitteesMeetingMaterials/Drugs/Reproduc tiveHealthDrugsAdvisoryCommittee/ UCM176605.pdf [Accessed 2010 Dec 3]
20. Strom O, Macarios D, Badamgarav E, et al. Costeffectiveness model for denosumab incorporating FRAX® and adherence in a UK setting [abstract]. Osteoporos Int 2009; 20 Suppl. 1: 20
21. Hiligsmann M, Reginster JY. Cost-utility of denosumab for the treatment of postmenopausal osteoporotic women [abstract]. Osteoporos Int 2009; 20 Suppl. 1: 16
22. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008; 19 (4): 385-97
23. National Institute for Health and Clinical Excellence. Osteoporosis: secondary prevention including strontium ranelate. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. London: NICE, 2010 [online]. Available from URL: http://www.nice.org.uk/TA161 [Accessed 2010Dec 3]
24. National Institute for Health and Clinical Excellence. Denosumab for the prevention of osteoporotic fractures in postmenopausal women: appraisal consultation document. London: NICE, 2010 [online]. Available from URL: http:// guidance.nice.org.uk/TA/Wave20/75/Consultation/Draft NICEGuidance [Accessed 2010 Dec 3]
25. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of non-vertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90: 2816-22 (Pubitemid 40686329)
26. Reginster JY, Felsenberg D, Boonen S, et al. Effects of longterm strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebocontrolled trial. Arthritis Rheum 2008; 58 (6): 1687-95 (Pubitemid 351847521)
27. Black D, Eastell R, Cosman F, et al. Efficacy of once-yearly zoledronic acid 5mg on a sub-set of six non-vertebral fractures [poster no. 360]. 31st Annual Meeting of the American Society for Bone and Mineral Research; 2009 Sep 11-15; Denver (CO) [online]. Available from URL: http://www.asbmr.org/Meetings/ AnnualMeeting/Abstract Detail.aspx?aid=f6a118a8-e20f-45a3-a03f-d7083bc551ca [Accessed 2010 Dec 3]
28. National Institute for Health and Clinical Excellence. Osteoporotic fractures: denosumab. Final appraisal determination. London: NICE, 2010 Sep [online]. Available from URL: http://guidance.nice.org.uk/TA/Wave20/75/FAD [Accessed 2010 Dec 3]